TomoBreast randomized clinical trial's lung-heart outcomes and mortality through the 2020 COVID-19 pandemic: data and software

<p>Dataset and R script to reproduce the analyses of the manuscript:</p> <p>Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M.</p> <p><strong>Lung-heart outcomes and mortality through the 2020 COVID-19 pandemic in a prospective cohort of breast cancer radiotherapy patients.</strong></p> <p>Cancers 2022;&nbsp;14(24):6241. https:// doi.org/10.3390/cancers14246241</p> <p>https://www.mdpi.com/2072-6694/14/24/6241</p> <p>PubMed:&nbsp;PMID:&nbsp;36551726</p> <p>PMCID:&nbsp;PMC9777311</p> <p>Info on the variables in file&nbsp;"aelq6_public.R"</p> <p>reproduced in "aelq_2_3_readme.txt":</p> <p>"aelq2_base2.txt" = baseline characteristics.</p> <p>"aelq3.txt" = longitudinal maesurements.</p> <p>Variables in "aelq2_base2.txt":</p> <p>"<strong>aelq2_base2.txt</strong>" = baseline characteristics.&nbsp;<br># Age at randomization, years.&nbsp;<br># RTdose: cf TomoBreast papers.&nbsp;<br># 51 Gy = hypofractionated, simultaneous integrated boost<br># 42 Gy = hypofractionated, no boost, mastectomy cases only<br># 50 Gy = conventional, no boost, mastectomy cases only<br># 66 Gy = conventional, sequential boost<br># Weight kg, Height cm,&nbsp;<br># Detection 1=found by screening (senology follow-up/controle)<br># &nbsp;&nbsp; &nbsp;2=found by symptoms (pain, palpable)<br># &nbsp;&nbsp; &nbsp;9=unknown<br># Smoker &nbsp;&nbsp; &nbsp;0= Not smoker<br># &nbsp;&nbsp; &nbsp;1= Smoker<br># &nbsp;&nbsp; &nbsp;2=ex-smoker<br># Mastectomy (and other binary coded) 1= yes<br># chemosched 0=none<br># &nbsp;&nbsp; &nbsp;1= planned after RT (sequential)<br># &nbsp;&nbsp; &nbsp;2= prior to RT and is finished (sequential)<br># &nbsp;&nbsp; &nbsp;3= chemo is on-going or is planned to start with RT (concomitant)<br># hormonetherapy &nbsp;&nbsp; &nbsp;0=no<br># &nbsp;&nbsp; &nbsp;1=tamoxifen (nolvadex)<br># &nbsp;&nbsp; &nbsp;2=Femara (Letrozole)<br># &nbsp;&nbsp; &nbsp;3=zoladex<br># &nbsp;&nbsp; &nbsp;4=tamoxifen + zoladex<br># Laterality 1,=Right, 2=Left, 3=Bilateral<br># LengthFU: length of follow-up, days from randomization</p> <p>"<strong>aelq3.txt</strong>" = longitudinal maesurements.<br># "Nr" = Case ID<br># "Time" in days from origin (origin =date of randomization),&nbsp;<br># if negative =before randomization<br># &nbsp; &nbsp;"KPS" &nbsp; &nbsp; &nbsp; "Weight" &nbsp; &nbsp;<br># "Died" &nbsp; &nbsp; &nbsp;"LocalRec" &nbsp;"Metast" &nbsp; &nbsp;"NewPrim" &nbsp; = binary code, 0=no, 1=yes<br># "fAEBreast" "fAEHeart" &nbsp;"fAELung" &nbsp; "fAEOther"&nbsp;<br># fAE = freedom from breast, heart, lung, other adverse event score<br># "LVEF2" = ejection fraction, %<br># "MacIver" = estimated cardiac strain</p> <p># the following are pulmonary function tests, untransformed units<br># "FVC", "FEV1", "PEF", "VC", "TLC", "RV", "FRC", "Raw", "sRaw", "DLCO",<br># "VA", "PF"</p> <p># "fDY", "fFA", "fPA" = freedom from dyspnea, from fatigue, from pain<br># range 0 to 100 (best)<br># see papers:</p> <p># Van Parijs, H.; Vinh-Hung, V.; Fontaine, C.; Storme, G.; Verschraegen, C.;<br># Nguyen, D.M.; Adriaenssens, N.; Nguyen, N.P.; Gorobets, O.; De Ridder, M.<br># Cardiopulmonary-related patient-reported outcomes in a randomized clinical<br># trial of radiation therapy for breast cancer. BMC Cancer 2021, 21, 1177,<br># doi:10.1186/s12885-021-08916-z.</p> <p># preprint:<br># Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.;&nbsp;<br># Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.;<br># De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized&nbsp;<br># clinical trial of hypofractionated image guided radiation therapy for<br># breast cancer. Preprints 2022, 202212, 0214.<br># https://doi.org/10.20944/preprints202212.0214.v1</p> <p>#&nbsp;<br># "Year" = year of the observation<br># example: randomized 1/1/2011, measurement done 1/31/2011, time = 30 days,<br># Year =2011<br>#<br>&nbsp;</p>